Home

Eli Lilly (LLY)

808.61
+1.42 (0.18%)
NYSE · Last Trade: Jun 11th, 5:13 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
McDonald's Just Got Hammered By Weight-Loss Drugs — Twicebenzinga.com
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Via Benzinga · June 11, 2025
Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugsbenzinga.com
Eli Lilly signed a licensing deal with Juvena for muscle health using its AI-enabled stem-cell protein screening platform.
Via Benzinga · June 11, 2025
Should You Buy Eli Lilly Stock Before June 22?fool.com
Via The Motley Fool · June 11, 2025
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearishstocktwits.com
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications.
Via Stocktwits · June 11, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · June 10, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 10, 2025
McDonald's Stock Bitten By Big Downgrade Over Weight-Loss Drugsinvestors.com
The fast-food giant was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.
Via Investor's Business Daily · June 10, 2025
2 Weight Loss Drug Stocks That Are Screaming Buys in Junefool.com
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Tradingbenzinga.com
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodesstocktwits.com
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punchinvestors.com
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via Investor's Business Daily · June 9, 2025
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapybenzinga.com
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via Benzinga · June 9, 2025
5 Monster Stocks to Hold for the Next 10 Yearsfool.com
Via The Motley Fool · June 9, 2025
1 Stock Down 34% This Year to Buy and Holdfool.com
Via The Motley Fool · June 8, 2025
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Yearsfool.com
Via The Motley Fool · June 7, 2025
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via MarketBeat · June 7, 2025
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.investors.com
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025
Novo Nordisk Stock: Is It Still a Smart Buy?fool.com
Via The Motley Fool · June 6, 2025
Time to Buy These 3 Cheap Stocks?fool.com
Via The Motley Fool · June 5, 2025
Should You Invest $1,000 in Eli Lilly today?fool.com
Via The Motley Fool · June 5, 2025
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologicsstocktwits.com
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.
Via Stocktwits · June 4, 2025
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Pointbenzinga.com
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 4, 2025
The 9 Best Stocks to Buy Now in June (2025)fool.com
Via The Motley Fool · June 4, 2025
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Dealbenzinga.com
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Via Benzinga · June 4, 2025